 |
|
|
Press Releases
| Jun. 14, 2010 |
- |
3 of HBL's Portfolio Companies Appear in "Israel's Most Promising BioTech Statups" List
ProtAb, KAHR and CellCure included in the list
|
|
| Jun. 13, 2010 |
- |
From Test Tube to Bedside
Israel's only hospital affiliated biopark, located in Jerusalem, helps doctors conduct research
|
|
| Apr. 19, 2010 |
- |
"Swimming Against The Current"
9 Stocks on TASE Post Gains Even When the Market Doesn't
|
|
| Apr. 13, 2010 |
- |
Clal Biotechnology, Pontifax and Hadasit Bio-Holdings to invest $ 4 million in ProtAb, a wholly owned Hadasit Bio-Holdings portfolio company
The company is developing a novel monoclonal antibody for the treatment of Rheumatoid Arthritis and other autoimmune diseases such as Crohn’s Disease
|
|
| Mar. 28, 2010 |
- |
Hadassah Breakthrough Increases the Potential to Produce the Large Quantities of Human Embryonic Stem Cells Required For Transplantation
|
|
| Mar. 19, 2010 |
- |
Hadasit - One of "10 Promising Stocks for 2010"
|
|
| Mar. 11, 2010 |
- |
Hadasit Bio Holdings Exploits Its Competitive Advantage
As published in "Globes", March 10th, 2010
|
|
| Mar. 3, 2010 |
- |
Small But Promising Companies
New BioMed Index Attracts Investors in Israel Life Sciences
|
|
| Jan. 24, 2010 |
- |
Tel Aviv Stock Exchange to Launch BioMed Index
38 BioMed Companies on TASE. Index to Allow New Investment Vehicles
|
|
| Dec. 24, 2009 |
- |
KAHR Medical Raises 1.5 M Sheqels from Hadasit Bio-Holdings, Moves Towards Clinical Trial of Immune-system Diseases and Cancer
Invited to Present Preclinical Results at Major Scientific Conferences in Europe and the United States
|
|
| Dec. 6, 2009 |
- |
ProtAb, a Wholly Owned Subsidiary of Hadasit Bio-Holdings, Attracts Funding and Initiates the Manufacturing Process of its Lead Antibody in Preparation for Clinical Trials
|
|
| Nov. 17, 2009 |
- |
Hadasit Bio-Holdings Expands Activity to Diagnostic Markers for Cancer and Sets Up BioMarCare Technologies
The new company has begun a clinical trial of the first marker, for detection of various stages of breast cancer. HBL will inject 1.1 million NIS to bring the trial to completion.
|
|
| Jul. 6, 2009 |
- |
Jerusalem Mayor Nir Barkat Visits BioTechnology Park at Hadassah Ein Kerem
Mayor calls the Jerusalem BioPark a central element in the making of Jerusalem
|
|
| Feb. 26, 2009 |
- |
KAHR's Third Generation Biologics Attract Financing
Published in BioWorld Today, Feb. 19th, 2009
|
|
 |
|
 |
| |
Press Releases Archive
|
|
 |
|
 |
|
|
